The Safety and Immunogenicity of an Interleukin-12–Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection
Jeffrey M. Jacobson(Drexel University), Nicole Frahm(Fred Hutch Cancer Center), Jennifer Janik(Hospital of the University of Pennsylvania), Teresa Spitz(Washington University in St. Louis), A. L. Sánchez Martinez(Office of AIDS Research), John H. Eldridge(Profectus Biosciences (United States)), Pablo Tebas(University of Pennsylvania), Jennifer Tiu(Harvard University), M. Juliana McElrath(Fred Hutch Cancer Center), Anne F. Luetkemeyer(University of California, San Francisco), David B. Clifford(Washington University in St. Louis), Roy M. Matining(Cancer Research And Biostatistics), Lu Zheng(Harvard University), Cara C. Wilson(University of Colorado Health), Michael A. Egan(Profectus Biosciences (United States)), John Hural(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Alan Landay(The University of Texas Medical Branch at Galveston)
Cited by 38
Related Papers
Integrated analysis of multimodal single-cell data
|Cell|2021|16.2k
Microbial translocation is a cause of systemic immune activation in chronic HIV infection
|Nature Medicine|2006|3.6k
Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy
|New England Journal of Medicine|2006|792
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis
|The Lancet|2008|708
Plasma Levels of Bacterial DNA Correlate with Immune Activation and the Magnitude of Immune Restoration in Persons with Antiretroviral‐Treated HIV Infection
|The Journal of Infectious Diseases|2009|597